Peer-Reviewed Journal Details
Mandatory Fields
Paruch, K.,Dwyer, M. P.,Alvarez, C.,Brown, C.,Chan, T. Y.,Doll, R. J.,Keertikar, K.,Knutson, C.,McKittrick, B.,Rivera, J.,Rossman, R.,Tucker, G.,Fischmann, T.,Hruza, A.,Madison, V.,Nomeir, A. A.,Wang, Y.,Kirschmeier, P.,Lees, E.,Parry, D.,Sgambellone, N.,Seghezzi, W.,Schultz, L.,Shanahan, F.,Wiswell, D.,Xu, X.,Zhou, Q.,James, R. A.,Paradkar, V. M.,Park, H.,Rokosz, L. R.,Stauffer, T. M.,Guzi, T. J.
2010
August
Acs Med Chem Lettacs Med Chem Lett
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
Validated
()
Optional Fields
1
5
204
208
Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability. This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clinical evaluation.Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability. This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clinical evaluation.
1948-58751948-5875
Grant Details